ArticleMolecular therapy oncolytics2020

Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells.

Xinping Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.